Middle East Pharmaceutical Industries Company (TADAWUL:4016)

Market Cap	2.07B -21.7%
Revenue (ttm)	460.48M +16.9%
Net Income	97.01M +21.5%
EPS	4.85 +21.5%
Shares Out	20.00M
PE Ratio	21.34
Forward PE	17.37
Dividend	2.50 (2.46%)
Ex-Dividend Date	Mar 30, 2026

Volume	2,135
Average Volume	113,496
Open	103.60
Previous Close	103.50
Day's Range	103.00 - 103.90
52-Week Range	94.30 - 139.00
Beta	0.47
RSI	54.65
Earnings Date	Mar 26, 2026

About TADAWUL:4016

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. Its product portfolio includes dermatological, respiratory, cardiovascular, alimentary and anti-infectives, musculoskeletal, genitourinary systems, and CNS. It exports its products. The company was formerly known as Middle East Chemical Products Factory Compan...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 731
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4016

Financial Performance

In 2025, TADAWUL:4016's revenue was 460.48 million, an increase of 16.87% compared to the previous year's 394.00 million. Earnings were 97.01 million, an increase of 21.49%.